{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:07:02Z","timestamp":1788336422658,"version":"build-2803163510"},"reference-count":78,"publisher":"Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Altered miRNA expressions are assigned pathogenic properties in several cancers including mycosis fungoides and could play a role in the early onset of the disease. The aim of this study was to examine disease-specific miRNA expression in early-stage mycosis fungoides patch and plaque lesions. A quantitative real-time PCR platform of 384 human miRNAs was used to study miRNA expression in 154 diagnostic mycosis fungoides biopsies. A total of 110 miRNAs were significantly differentially expressed (&gt;2-fold, p\u2009&lt;\u20090.05) between plaque lesions and healthy controls, and 90 miRNAs (&gt;2-fold, p\u2009&lt;\u20090.05) differed between patch lesions and healthy controls. Moreover, 13 miRNAs differed in expression between patch and plaque lesions. Early-stage mycosis fungoides exhibited miRNA features that overlapped with those of psoriasis. However, 39 miRNAs, including miR-142-3p, miR-150 and miR-146b, were specific to mycosis fungoides. In conclusion, early-stage mycosis fungoides expresses a distinct miRNA profile, indicating that miRNAs could play a role in the early development of mycosis fungoides.<\/jats:p>","DOI":"10.2340\/actadv.v102.628","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T09:47:16Z","timestamp":1657014436000},"page":"adv00785","source":"Crossref","is-referenced-by-count":8,"title":["miRNA Signature in Early-stage Mycosis Fungoides"],"prefix":"10.2340","volume":"102","author":[{"given":"Sissel T.","family":"S\u00f8rensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Litman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Celis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Torres-Rusillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Willerslev-Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"\u00d8dum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise M.","family":"Lindahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"key":"21960","doi-asserted-by":"crossref","unstructured":"Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113: 5064-5073.","DOI":"10.1182\/blood-2008-10-184168"},{"key":"21961","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2008-10-184168","DOI":"10.1182\/blood-2008-10-184168"},{"key":"21962","doi-asserted-by":"crossref","unstructured":"Ahn CS, A AL, Sangueza OP. Mycosis fungoides: an updated review of clinicopathologic variants. Am J Dermatopathol 2014; 36: 933-948; quiz 949-951.","DOI":"10.1097\/DAD.0000000000000207"},{"key":"21963","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/DAD.0000000000000207","DOI":"10.1097\/DAD.0000000000000207"},{"key":"21964","doi-asserted-by":"crossref","unstructured":"Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.","DOI":"10.1182\/blood-2004-09-3502"},{"key":"21965","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2004-09-3502","DOI":"10.1182\/blood-2004-09-3502"},{"key":"21966","doi-asserted-by":"crossref","unstructured":"Pimpinelli N, Olsen EA, Santucci M, Vonderheid E, Haeffner AC, Stevens S, et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005; 53: 1053-1063.","DOI":"10.1016\/j.jaad.2005.08.057"},{"key":"21967","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2005.08.057","DOI":"10.1016\/j.jaad.2005.08.057"},{"key":"21968","doi-asserted-by":"crossref","unstructured":"Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010; 28: 4730-4739.","DOI":"10.1200\/JCO.2009.27.7665"},{"key":"21969","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2009.27.7665","DOI":"10.1200\/JCO.2009.27.7665"},{"key":"21970","doi-asserted-by":"crossref","unstructured":"MacKie RM. Initial event in mycosis fungoides of the skin is viral infection of epidermal Langerhans cells. Lancet 1981; 2: 283-285.","DOI":"10.1016\/S0140-6736(81)90529-8"},{"key":"21971","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(81)90529-8","DOI":"10.1016\/S0140-6736(81)90529-8"},{"key":"21972","doi-asserted-by":"crossref","unstructured":"Willerslev-Olsen A, Krejsgaard T, Lindahl LM, Bonefeld CM, Wasik MA, Koralov SB, et al. Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma. Toxins (Basel) 2013; 5: 1402-1421.","DOI":"10.3390\/toxins5081402"},{"key":"21973","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/toxins5081402","DOI":"10.3390\/toxins5081402"},{"key":"21974","doi-asserted-by":"crossref","unstructured":"Willerslev-Olsen A, Krejsgaard T, Lindahl LM, Litvinov IV, Fredholm S, Petersen DL, et al. Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood 2016; 127: 1287-1296.","DOI":"10.1182\/blood-2015-08-662353"},{"key":"21975","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2015-08-662353","DOI":"10.1182\/blood-2015-08-662353"},{"key":"21976","doi-asserted-by":"crossref","unstructured":"Krejsgaard T, Willerslev-Olsen A, Lindahl LM, Bonefeld CM, Koralov SB, Geisler C, et al. Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation. Blood 2014; 124: 761-770.","DOI":"10.1182\/blood-2014-01-551184"},{"key":"21977","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2014-01-551184","DOI":"10.1182\/blood-2014-01-551184"},{"key":"21978","doi-asserted-by":"crossref","unstructured":"Jackow CM, Cather JC, Hearne V, Asano AT, Musser JM, Duvic M. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood 1997; 89: 32-40.","DOI":"10.1182\/blood.V89.1.32.32_32_40"},{"key":"21979","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood.V89.1.32.32_32_40","DOI":"10.1182\/blood.V89.1.32.32_32_40"},{"key":"21980","doi-asserted-by":"crossref","unstructured":"Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sezary syndrome. Br J Dermatol 2008; 159: 105-112.","DOI":"10.1111\/j.1365-2133.2008.08612.x"},{"key":"21981","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08612.x","DOI":"10.1111\/j.1365-2133.2008.08612.x"},{"key":"21982","doi-asserted-by":"crossref","unstructured":"Lindahl LM, Willerslev-Olsen A, Gjerdrum LMR, Nielsen PR, Blumel E, Rittig AH, et al. Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. Blood 2019; 134: 1072-1083.","DOI":"10.1182\/blood.2018888107"},{"key":"21983","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood.2018888107","DOI":"10.1182\/blood.2018888107"},{"key":"21984","doi-asserted-by":"crossref","unstructured":"Odum N, Lindahl LM, Wod M, Krejsgaard T, Skytthe A, Woetmann A, et al. Investigating heredity in cutaneous T-cell lymphoma in a unique cohort of Danish twins. Blood Cancer J 2017; 7: e517.","DOI":"10.1038\/bcj.2016.128"},{"key":"21985","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/bcj.2016.128","DOI":"10.1038\/bcj.2016.128"},{"key":"21986","doi-asserted-by":"crossref","unstructured":"Litvinov IV, Tetzlaff MT, Thibault P, Gangar P, Moreau L, Watters AK, et al. Gene expression analysis in cutaneous T-cell lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators. Oncoimmunology 2017; 6: e1306618.","DOI":"10.1080\/2162402X.2017.1306618"},{"key":"21987","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/2162402X.2017.1306618","DOI":"10.1080\/2162402X.2017.1306618"},{"key":"21988","doi-asserted-by":"crossref","unstructured":"Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet 2015; 47: 1011-1019.","DOI":"10.1038\/ng.3356"},{"key":"21989","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/ng.3356","DOI":"10.1038\/ng.3356"},{"key":"21990","doi-asserted-by":"crossref","unstructured":"Lindahl LM, Fredholm S, Joseph C, Nielsen BS, Jonson L, Willerslev-Olsen A, et al. STAT5 induces miR-21 expression in cutaneous T cell lymphoma. Oncotarget 2016; 7: 45730-45744.","DOI":"10.18632\/oncotarget.10160"},{"key":"21991","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.18632\/oncotarget.10160","DOI":"10.18632\/oncotarget.10160"},{"key":"21992","doi-asserted-by":"crossref","unstructured":"Sibbesen NA, Kopp KL, Litvinov IV, Jonson L, Willerslev-Olsen A, Fredholm S, et al. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma. Oncotarget 2015; 6: 20555-20569.","DOI":"10.18632\/oncotarget.4111"},{"key":"21993","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.18632\/oncotarget.4111","DOI":"10.18632\/oncotarget.4111"},{"key":"21994","doi-asserted-by":"crossref","unstructured":"Lindahl LM, Besenbacher S, Rittig AH, Celis P, Willerslev-Olsen A, Gjerdrum LMR, et al. Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study. Blood 2018; 131: 759-770.","DOI":"10.1182\/blood-2017-06-788950"},{"key":"21995","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2017-06-788950","DOI":"10.1182\/blood-2017-06-788950"},{"key":"21996","doi-asserted-by":"crossref","unstructured":"Ralfkiaer U, Hagedorn PH, Bangsgaard N, Lovendorf MB, Ahler CB, Svensson L, et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood 2011; 118: 5891-5900.","DOI":"10.1182\/blood-2011-06-358382"},{"key":"21997","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2011-06-358382","DOI":"10.1182\/blood-2011-06-358382"},{"key":"21998","doi-asserted-by":"crossref","unstructured":"van Kester MS, Ballabio E, Benner MF, Chen XH, Saunders NJ, van der Fits L, et al. miRNA expression profiling of mycosis fungoides. Mol Oncol 2011; 5: 273-280.","DOI":"10.1016\/j.molonc.2011.02.003"},{"key":"21999","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.molonc.2011.02.003","DOI":"10.1016\/j.molonc.2011.02.003"},{"key":"22000","doi-asserted-by":"crossref","unstructured":"Ballabio E, Mitchell T, van Kester MS, Taylor S, Dunlop HM, Chi J, et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood 2010; 116: 1105-1113.","DOI":"10.1182\/blood-2009-12-256719"},{"key":"22001","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2009-12-256719","DOI":"10.1182\/blood-2009-12-256719"},{"key":"22002","doi-asserted-by":"crossref","unstructured":"Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.","DOI":"10.1016\/S0092-8674(04)00045-5"},{"key":"22003","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0092-8674(04)00045-5","DOI":"10.1016\/S0092-8674(04)00045-5"},{"key":"22004","doi-asserted-by":"crossref","unstructured":"Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.","DOI":"10.1038\/nrc1840"},{"key":"22005","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/nrc1840","DOI":"10.1038\/nrc1840"},{"key":"22006","unstructured":"Ralfkiaer U, Lindahl LM, Litman T, Gjerdrum LM, Ahler CB, Gniadecki R, et al. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma. Anticancer Res 2014; 34: 7207-7217."},{"key":"22007","doi-asserted-by":"crossref","unstructured":"Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722.","DOI":"10.1182\/blood-2007-03-055749"},{"key":"22008","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2007-03-055749","DOI":"10.1182\/blood-2007-03-055749"},{"key":"22009","doi-asserted-by":"crossref","unstructured":"Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet 2012; 13: 358-369.","DOI":"10.1038\/nrg3198"},{"key":"22010","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/nrg3198","DOI":"10.1038\/nrg3198"},{"key":"22011","doi-asserted-by":"crossref","unstructured":"Islam F, Gopalan V, Vider J, Lu CT, Lam AK. MiR-142-5p act as an oncogenic microRNA in colorectal cancer: clinicopathological and functional insights. Exp Mol Pathol 2018; 104: 98-107.","DOI":"10.1016\/j.yexmp.2018.01.006"},{"key":"22012","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.yexmp.2018.01.006","DOI":"10.1016\/j.yexmp.2018.01.006"},{"key":"22013","doi-asserted-by":"crossref","unstructured":"Xu W, Wang W. MicroRNA1425p modulates breast cancer cell proliferation and apoptosis by targeting phosphatase and tensin homolog. Mol Med Rep 2018; 17: 7529-7536.","DOI":"10.3892\/mmr.2018.8812"},{"key":"22014","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3892\/mmr.2018.8812","DOI":"10.3892\/mmr.2018.8812"},{"key":"22015","unstructured":"Liu L, Liu S, Duan Q, Chen L, Wu T, Qian H, et al. MicroRNA-142-5p promotes cell growth and migration in renal cell carcinoma by targeting BTG3. Am J Transl Res 2017; 9: 2394-2402."},{"key":"22016","doi-asserted-by":"crossref","unstructured":"Aucher A, Rudnicka D, Davis DM. MicroRNAs transfer from human macrophages to hepato-carcinoma cells and inhibit proliferation. J Immunol 2013; 191: 6250-6260.","DOI":"10.4049\/jimmunol.1301728"},{"key":"22017","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.4049\/jimmunol.1301728","DOI":"10.4049\/jimmunol.1301728"},{"key":"22018","doi-asserted-by":"crossref","unstructured":"Sandoval J, Diaz-Lagares A, Salgado R, Servitje O, Climent F, Ortiz-Romero PL, et al. MicroRNA expression profiling and DNA methylation signature for deregulated microRNA in cutaneous T-cell lymphoma. J Invest Dermatol 2015; 135: 1128-1137.","DOI":"10.1038\/jid.2014.487"},{"key":"22019","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/jid.2014.487","DOI":"10.1038\/jid.2014.487"},{"key":"22020","doi-asserted-by":"crossref","unstructured":"Cristofoletti C, Picchio MC, Lazzeri C, Tocco V, Pagani E, Bresin A, et al. Comprehensive analysis of PTEN status in Sezary syndrome. Blood 2013; 122: 3511-3520.","DOI":"10.1182\/blood-2013-06-510578"},{"key":"22021","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2013-06-510578","DOI":"10.1182\/blood-2013-06-510578"},{"key":"22022","doi-asserted-by":"crossref","unstructured":"Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010; 39: 493-506.","DOI":"10.1016\/j.molcel.2010.07.023"},{"key":"22023","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.molcel.2010.07.023","DOI":"10.1016\/j.molcel.2010.07.023"},{"key":"22024","doi-asserted-by":"crossref","unstructured":"Kadera BE, Li L, Toste PA, Wu N, Adams C, Dawson DW, et al. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. PLoS One 2013; 8: e71978.","DOI":"10.1371\/journal.pone.0071978"},{"key":"22025","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1371\/journal.pone.0071978","DOI":"10.1371\/journal.pone.0071978"},{"key":"22026","doi-asserted-by":"crossref","unstructured":"Bullock MD, Pickard KM, Nielsen BS, Sayan AE, Jenei V, Mellone M, et al. Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression. Cell Death Dis 2013; 4: e684-e684.","DOI":"10.1038\/cddis.2013.213"},{"key":"22027","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/cddis.2013.213","DOI":"10.1038\/cddis.2013.213"},{"key":"22028","doi-asserted-by":"crossref","unstructured":"Wang J, Li Y, Ding M, Zhang H, Xu X, Tang J. Molecular mechanisms and clinical applications of miR-22 in regulating malignant progression in human cancer (Review). Int J Oncol 2017; 50: 345-355.","DOI":"10.3892\/ijo.2016.3811"},{"key":"22029","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3892\/ijo.2016.3811","DOI":"10.3892\/ijo.2016.3811"},{"key":"22030","doi-asserted-by":"crossref","unstructured":"Song SJ, Pandolfi PP. MicroRNAs in the pathogenesis of myelodysplastic syndromes and myeloid leukaemia. Curr Opin Hematol 2014; 21: 276-282.","DOI":"10.1097\/MOH.0000000000000054"},{"key":"22031","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/MOH.0000000000000054","DOI":"10.1097\/MOH.0000000000000054"},{"key":"22032","doi-asserted-by":"crossref","unstructured":"Wu H, Liu J, Zhang Y, Li Q, Wang Q, Gu Z. miR-22 suppresses cell viability and EMT of ovarian cancer cells via NLRP3 and inhibits PI3K\/AKT signaling pathway. Clin Transl Oncol 2021; 23: 257-264.","DOI":"10.1007\/s12094-020-02413-8"},{"key":"22033","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s12094-020-02413-8","DOI":"10.1007\/s12094-020-02413-8"},{"key":"22034","doi-asserted-by":"crossref","unstructured":"Gluud M, Willerslev-Olsen A, Gjerdrum LMR, Lindahl LM, Buus TB, Andersen MH, et al. MicroRNAs in the pathogenesis, diagnosis, prognosis and targeted treatment of cutaneous T-cell lymphomas. Cancers (Basel) 2020; 12: 1229.","DOI":"10.3390\/cancers12051229"},{"key":"22035","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/cancers12051229","DOI":"10.3390\/cancers12051229"},{"key":"22036","doi-asserted-by":"crossref","unstructured":"L\u00f8vendorf MB, Zibert JR, Hagedorn PH, Glue C, \u00d8dum N, R\u00f8pke MA, et al. Comparison of microRNA expression using different preservation methods of matched psoriatic skin samples. Exp Dermatol 2012; 21: 299-301.","DOI":"10.1111\/j.1600-0625.2012.01445.x"},{"key":"22037","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1600-0625.2012.01445.x","DOI":"10.1111\/j.1600-0625.2012.01445.x"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/628\/7324","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/628\/7327","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/628\/7324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T09:19:36Z","timestamp":1664875176000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":78,"URL":"https:\/\/doi.org\/10.2340\/actadv.v102.628","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,4]]}}}